Search

Allogene Therapeutics Inc

Suletud

SektorTervishoid

1.96 -1.01

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.95

Max

1.97

Põhinäitajad

By Trading Economics

Sissetulek

-70K

-43M

Müük

4.6M

4.6M

Aktsiakasum

-0.13

Kasumimarginaal

-919.763

Töötajad

150

EBITDA

-251K

-40M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+420.3% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-34M

691M

Eelmine avamishind

2.97

Eelmine sulgemishind

1.96

Uudiste sentiment

By Acuity

37%

63%

96 / 339 Pingereas Healthcare

Allogene Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. sept 2026, 19:36 UTC

Allogene Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains near the midpoint of its one-month trading range.

31. aug 2026, 19:16 UTC

News

Allogene Therapeutics Inc shares are lower amid broader market declines following hawkish Fed comments. The company noted progress with cema-cel and FDA designations.

28. aug 2026, 23:36 UTC

Allogene Therapeutics Inc shares are higher in after-market trading. No specific news was identified to explain this movement.

27. aug 2026, 23:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the decline, though the stock has gained over the past month.

26. aug 2026, 19:56 UTC

Allogene Therapeutics Inc shares are lower during Wednesday's session, continuing a decline since Tuesday amid broader market concerns over persistent inflationary pressures.

25. aug 2026, 23:56 UTC

Allogene Therapeutics Inc. is trading roughly flat in after-market hours, maintaining a position near the upper end of its one-month range.

24. aug 2026, 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though this marks the fifth consecutive day of lower closes for the asset.

21. aug 2026, 19:56 UTC

Allogene Therapeutics Inc. shares are lower today, fluctuating within a routine range but remaining above their 20-day moving average.

20. aug 2026, 22:16 UTC

Allogene Therapeutics Inc. shares are higher in after-market hours, despite earlier declines, amid rising U.S. Treasury yields and broader market pressure.

19. aug 2026, 23:01 UTC

Allogene Therapeutics Inc. shares are lower in after-market hours, continuing a decline that began at the start of the session.

18. aug 2026, 19:51 UTC

Correlated Moves

Allogene Therapeutics Inc. shares are trading lower amid broader market declines and rising Treasury yields, reflecting ongoing pressure in the biotechnology sector.

17. aug 2026, 19:16 UTC

Correlated Moves
News

Allogene Therapeutics Inc shares rise following Citizens' Market Outperform rating and $6 price target. The broader Biotechnology sector also shows significant gains.

14. aug 2026, 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement. The stock remains above its 20-day moving average.

13. aug 2026, 19:26 UTC

News

Allogene Therapeutics reported a net loss of $42.7 million, better than expectations, as shares trade lower amid concerns over a potential $500 million offering.

12. aug 2026, 23:21 UTC

News

Allogene Therapeutics reports narrower net loss of $42.7 million, revenue of $4.64 million. Shares higher after positive trial results and $500 million securities offering announcement.

11. aug 2026, 23:26 UTC

Allogene Therapeutics shares advanced during after-market hours, trading within a narrow range and remaining well above the 20-day moving average.

10. aug 2026, 19:16 UTC

Allogene Therapeutics is trading higher, maintaining upward momentum despite a decline in U.S. stock futures following a labor market report.

7. aug 2026, 19:16 UTC

Correlated Moves

Biotechnology stocks are rising, boosting Allogene Therapeutics shares. The ARK Genomic Revolution ETF has also increased, reflecting positive sector momentum.

6. aug 2026, 19:46 UTC

Correlated Moves

Allogene Therapeutics shares are lower, reflecting broader market trends, as the Russell 2000 Index also declined during Thursday's session.

5. aug 2026, 22:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting a pullback from earlier gains amid broader market volatility following weaker U.S. job growth data.

3. aug 2026, 20:06 UTC

Allogene Therapeutics Inc. shares are trading lower, continuing a decline since Friday's close, despite broader market gains in the S&P 500 and Nasdaq 100.

30. juuli 2026, 20:04 UTC

Correlated Moves
Event

Allogene Therapeutics receives RMAT and Fast Track designations from the FDA for cema-cel, contributing to gains in shares today.

29. juuli 2026, 23:51 UTC

Event
Correlated Moves

Allogene Therapeutics receives FDA RMAT and Fast Track designations for cema-cel, boosting shares higher in after-market hours. The Russell 2000 Index's rise may also contribute.

28. juuli 2026, 20:02 UTC

Allogene Therapeutics Inc shares are lower amid negative market sentiment following a significant sell-off in technology stocks across Asian markets.

27. juuli 2026, 18:07 UTC

Allogene Therapeutics Inc shares are higher today, despite earlier fluctuations. The market backdrop features a decline in oil prices, easing inflation concerns.

24. juuli 2026, 19:46 UTC

Correlated Moves

Allogene Therapeutics Inc is lower today amid broader market declines, with the Russell 2000 Index down and oil price volatility impacting the biotechnology sector.

23. juuli 2026, 22:56 UTC

Allogene Therapeutics Inc. shares are roughly flat in after-market trading, remaining below their 20-day moving average and near the lower end of their one-month range.

22. juuli 2026, 20:13 UTC

Correlated Moves

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21. juuli 2026, 18:46 UTC

Correlated Moves
Social Media

Allogene Therapeutics shares are higher following positive TRAVERSE trial results for ALLO-316, which showed a 25% overall response rate in patients.

20. juuli 2026, 23:26 UTC

Allogene Therapeutics Inc. shares are higher in after-market trading, with no specific news identified. Broader market volatility continues to influence investor sentiment.

Võrdlus sarnastega

Hinnamuutus

Allogene Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

420.3% tõus

12 kuu keskmine prognoos

Keskmine 10.25 USD  420.3%

Kõrge 14 USD

Madal 8 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Allogene Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

6

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

96 / 339 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat